Notices. Notice
426 words·~2 min read·
/register/2021/02/04/2021-02294A research copy — for the controlling text, always check the official state or federal source. Not legal advice.
BILLING CODE 4140-01-P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Government-Owned Inventions; Availability for Licensing AGENCY: National Institutes of Health, HHS. ACTION: Notice. SUMMARY: The invention listed below is owned by an agency of the U.S. Government and is available for licensing as a biological material to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.
FOR FURTHER INFORMATION CONTACT: Jeffrey Thruston at 301-594-5179 or *jeffrey.thruston@nih.gov* . Licensing information may be obtained by communicating with the Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases, 5601 Fishers Lane, Rockville, MD 20852; tel. 301-496-2644. A signed Confidential Disclosure Agreement will be required to receive copies of unpublished information related to the invention. SUPPLEMENTARY INFORMATION:
Technology description follows: A VSV-EBOV-Based Vaccine Against COVID-19 Description of Technology Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of for coronavirus disease 2019 (COVID-19). COVID-19 is characterized by fever, cough, difficulty breathing, loss of taste and smell, nausea, and sore throat. As of the fourth quarter 2020, COVID-19 is responsible for over 1.17 million deaths worldwide. As the pandemic continues to surge, the importance of a safe, affordable, and efficacious vaccine is of urgent importance.
The present technology utilizes the well characterized vesicular stomatitis virus
(VSV)encoding the Ebola virus (VSV-EBOV) to express additionally a codon-optimized SARS-CoV-2 spike protein. A single intranasal or intramuscular administration of the vaccine showed protective efficacy against COVID-19 in hamsters after 4 weeks. A single intramuscular injection showed protective efficacy against COVID-19 pneumonia in rhesus macaques within 10 days. The vaccine is inexpensive to replicate, elicits a high antigen-specific antibody titer within the host, and provides protective efficacy after a single dose. This technology is available for licensing, as a biological material, for commercial development in accordance with 35 U.S.C. 209 and 37 CFR part 404. Potential Commercial Applications • Single dose vaccine against COVID-19 Competitive Advantages • Utilizes the established and well characterized VSV-EBOV vector • Expresses high antigen titers within host cells • Single dose protective efficacy against COVID-19 • Inexpensive and replicable Development Stage • Prototype • In vivo/In vitro *Inventors:* Andrea Marzi (NIAID), Wakako Asada (NIAID). *Licensing Contact:* To license this technology, please contact Jeffrey Thruston at 301-594-5179 or *jeffrey.thruston@nih.gov,* and reference E-233-2017-0. Dated: January 19, 2021. Surekha Vathyam, Deputy Director, Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases. [FR Doc. 2021-02294 Filed 2-3-21; 8:45 am]
Connectionstraces to 1
Traces to 1 document
1 reference not yet in our index
- 37 CFR 404
Citation graph
cites case law
Cites 2Cited by 0 across 0 sources